News | Coronavirus (COVID-19) | March 24, 2020

CDRH Issues Letter to Industry on COVID-19

The FDA issued a Letter to Industry that includes steps the FDA’s Center for Devices and Radiological Health (CDRH) has taken to prioritize work that advances the nation’s response during the Coronavirus Disease 2019 (COVID-19) public health emergency

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

March 24, 2020 — The U.S. Food and Drug Administration (FDA) issued a Letter to Industry that includes steps the FDA’s Center for Devices and Radiological Health (CDRH) has taken to prioritize work that advances the nation’s response during the Coronavirus Disease 2019 (COVID-19) public health emergency.

These steps seek to address the impact of the COVID-19 public health emergency on day-to-day operations in CDRH and in the medical device industry, while ensuring that government and private sector efforts to respond to this national emergency receive the highest priority.

The letter, dated March 23, 2020, reads as follows:

In response to the Coronavirus Disease 2019 (COVID-19) public health emergency,1 FDA’s Center for Devices and Radiological Health (CDRH) has taken the steps described in this letter to prioritize work that advances the nation’s response during this national emergency.2 These steps seek to address the impact of the COVID-19 public health emergency on day-to-day operations in CDRH and in the medical device industry, while ensuring that government and private sector efforts to respond to this national emergency receive the highest priority.

CDRH Has Converted In-Person Meetings with Industry to Teleconferences

Where possible, CDRH is leveraging technology to host teleconferences rather than in-person meetings with industry scheduled through April 30, 2020. We are converting each meeting to a teleconference to be held at the same date and time. We believe we have contacted all parties with meetings scheduled through April 30, 2020 to provide teleconference information. If you have not received teleconference information, please reach out to the CDRH staff member who originally scheduled your meeting. We will continue to assess whether any in-person meetings scheduled later than April 30, 2020 should be converted to teleconferences and will provide periodic updates.

Processing of Incoming Documents

The Document Control Center continues to receive and process incoming documents. In order to ensure the security of your information, we are generally unable to accept incoming submissions via email. In addition, existing systems have file size limitations associated with email. We are looking into electronic options other than email. We regret any delays this may cause you.

Extension of Response Due Dates for Marketing Applications Currently on Hold

For marketing applications on hold as of March 16, 2020, where the response due date is on or before April 30, 2020, CDRH has extended response due dates by 60 days for Premarket Notifications (510(k)s), Premarket Approval (PMA) applications (original and supplements), Humanitarian Device Exemption (HDE) applications (original and supplements) and De Novo classification requests. CDRH intends to extend this due date automatically; no extension requests are necessary to be submitted.

For additional submission types where a response or report is due (e.g., Post Approval or 522 Study reports, Investigational Device Exemption annual reports, PMA reports), we encourage you to submit the response or report when possible.

Please address any questions about response due dates to [email protected].

How to Submit an Inquiry or Request for an Emergency Use Authorization

On Fe. 4, 2020, the HHS Secretary determined that there is a public health emergency that involves the virus that causes COVID-19. On that same date, the Secretary declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 and on March 4, 2020, the Secretary made the declaration with respect to personal respiratory protective devices. Under FDA’s emergency use authorities, the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in certain emergencies to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives. We strongly encourage applicants to submit pre-EUAs to discuss technologies that might help address this emergency.

More information about current EUAs is on the FDA’s Emergency Use Authorization web page. For inquiries related to EUAs for in vitro diagnostics (IVDs), contact [email protected] For inquiries related to EUAs related to non-IVD medical devices, contact [email protected] For more information about the EUA program, please see the guidance, Emergency Use Authorization of Medical Products and Related Authorities.

COVID-19 Related Guidance Documents

FDA has issued immediately in effect guidance documents related to COVID-19. For the latest information, please see the FDA’s COVID-19 Related Guidance Documents web page.

 

References:

1 On January 31, 2020, the Secretary of Health and Human Services Alex M. Azar, issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS, Determination that a Public Health Emergency Exists. Jan. 31, 2020. (Accessible at https://www.phe.gov/emergency/news/healthactions/phe/Pages/2019-nCoV.aspx. 2 On March 13, 2020, the President declared a national emergency in response to COVID-19. President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19). Mar. 13, 2020. (Accessible at https://www.whitehouse.gov/presidential-actions/proclamation-declaring-national-emergency-concerningnovel-coronavirus-disease-covid-19-outbreak/). U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov

Related Coronavirus Content:

Qure.ai Launches Solutions to Help Tackle COVID19 

ASRT Deploys COVID-19 Resources for Educational Programs

Study Looks at CT Findings of COVID-19 Through Recovery

VIDEO: Imaging COVID-19 With Point-of-Care Ultrasound (POCUS)

The Cardiac Implications of Novel Coronavirus

CT Provides Best Diagnosis for Novel Coronavirus (COVID-19)

Radiology Lessons for Coronavirus From the SARS and MERS Epidemics

Deployment of Health IT in China’s Fight Against the COVID-19 Epidemic

Emerging Technologies Proving Value in Chinese Coronavirus Fight

Radiologists Describe Coronavirus CT Imaging Features

Coronavirus Update from the FDA

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Chest CT Findings of Patients Infected With Novel Coronavirus 2019-nCoV Pneumonia 

Find more related clinical content Coronavirus (COVID-19)

Related Content

These MRI scans show diffuse white matter abnormality (DWMA). The top three panels display raw MRI images from very preterm infants born at 27 weeks (left), 26 weeks (center) and 31 weeks (right) gestation.

These MRI scans show diffuse white matter abnormality (DWMA). The top three panels display raw MRI images from very preterm infants born at 27 weeks (left), 26 weeks (center) and 31 weeks (right) gestation. Higher signal intensity can be seen in the central white matter, particularly for the 31-week gestation infant. The bottom panels display the corresponding slices with objectively segmented DWMA in yellow. The 27-week infant (left) was diagnosed with mild DWMA, the 26-week infant (center) was diagnosed with moderate DWMA, and the 31-week infant had severe DWMA. Image courtesy of Cincinnati Children's and Nature Scientific Reports

News | Magnetic Resonance Imaging (MRI) | October 01, 2020
October 1, 2020 — As many as 70% of very premature infants (born earlier than 32 weeks gestation) show signs of white
Newly released study results present a strong case for lung cancer screening in New Zealand — particularly for Māori whose mortality rates are between three and four times higher than other ethnic groups.

Image courtesy of Siemens Healthineers

News | Lung Imaging | September 30, 2020
September 30, 2020 — Newly released study results present a strong case for...
The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

The artificial intelligence-driven Caption Guidance software guides point of care ultrasound (POCUS) users to get optimal cardiac ultrasound images. The AI software is an example of a FDA-cleared software that is helping improve imaging, even when used by less experienced users.

Feature | Artificial Intelligence | September 29, 2020 | Joe Fornadel, J.D., and Wes Moran, J.D.
The number of Federal Drug Administration (FDA)-approved AI-based algorithms is significant and has grown at a steady
The FDA Center for Devices and Radiological Health's COVID-19 response by the numbers between January 1 and September 18, 2020.

The FDA Center for Devices and Radiological Health's COVID-19 response by the numbers between January 1 and September 18, 2020. Graphic courtesy of FDA

News | Coronavirus (COVID-19) | September 29, 2020
September 29, 2020 — On September 28, FDA Commissioner of Food and Drugs...
Lung and respiratory health pioneer paves way for more precise care of complex respiratory conditions
News | Artificial Intelligence | September 25, 2020
September 25, 2020 — VIDA Diagnostics, Inc. announced that it has received 510(k) clearance from the Food and Drug Ad